The molecular genetics of gastroenteropancreatic neuroendocrine tumors
- 28 October 2005
- Vol. 104 (11), 2292-2309
- https://doi.org/10.1002/cncr.21451
Abstract
The pathobiology of neuroendocrine tumors (NETs) is hampered by the lack of scientific tools that define their mechanisms of secretion, proliferation, and metastasis; and, currently, there are no accurate means to assess tumor behavior and disease prognosis. Molecular biologic techniques and genetic analysis may facilitate the delineation of the molecular pathology of NETs and provide novel insights into their cellular mechanisms. The current status and recent advances in assessment of the molecular basis of tumorigenesis of gastroenteropancreatic neuroendocrine tumors (GEP‐NETs) were reviewed (1981–2004). The objectives of this retrospective study were to provide a cohesive overview of the current state of knowledge and to develop a molecular understanding of these rare tumor entities to facilitate the establishment of therapeutic targets and rational management strategies. Multiple differences in chromosomal aberration patterns were noted between gastrointestinal (GI) neuroendocrine and pancreatic endocrine tumors (PETs). Divergence in gene expression patterns in the development of GI carcinoids and PETs was identified, whereas examination of the PET and GI carcinoid data demonstrated only few areas of overlap in the accumulation of genetic aberrations. These data suggest that the recent World Health Organization classification of GEP‐NETs may require updating. In addition, previous assumptions of tumor similarity (pancreatic vs. GI) may be unfounded when they are examined at a molecular level. On the basis of the evolution of genetic information, enteric neuroendocrine lesions (carcinoids) and PETs may need to be classified as two distinct entities rather than grouped together as the single entity “GEP‐NETs.” Cancer 2005. © 2005 American Cancer Society.Keywords
This publication has 134 references indexed in Scilit:
- The significance of the Wnt pathway in the pathology of human cancersPathology, 2004
- RET and neuroendocrine tumorsCancer Letters, 2004
- Prognostic value of hMLH1 methylation and microsatellite instability in pancreatic endocrine neoplasmsSurgery, 2003
- HER 2/neu expression and gene amplification in colon cancerInternational Journal of Cancer, 2003
- A 5‐decade analysis of 13,715 carcinoid tumorsCancer, 2003
- Immunohistochemical prognostic indicators of gastrointestinal carcinoid tumoursEuropean Journal of Surgical Oncology, 2002
- Ampullary carcinoid and jejunal stromal tumour associated with von Recklinghausen's disease presenting as gastrointestinal bleeding and jaundiceEuropean Journal of Surgical Oncology, 2000
- Ampullary somatostatinoma associated with von Recklinghausen's neurofibromatosis presenting as obstructive jaundiceEuropean Journal of Surgical Oncology, 1996
- The molecular and genetic dissection of the retinoid signalling pathwayGene, 1993
- Epithelial cell adhesion moleculesExperimental Cell Research, 1986